Matthew W Foehr
CIK 1237556 · President and CEO · last filed 2026-04-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LGND price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OABIW | President and CEO | 4,420,492 | $0.39 | $1.71M | $7.27M | 33 | 2026-04-07 |
| VKTX | Director | 135,186 | $24.83 | $3.36M | -$286.7K | 11 | 2026-01-05 |
| LGND | President and COO | 162,187 | $311.93 | $50.59M | -$31.25M | 58 | 2022-11-03 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 46,250 | $4.60 | $212.7K | -$79.9K | 8 | 2021-03-25 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 5,545 | — | — | $133.1K | 12 | 2020-04-23 |
| Viking Therapeutics, Inc. (VKTX.W) Delisted | Director | 26,250 | — | — | $24.8K | 1 | 2016-04-13 |
Recent Filings · Page 4 of 14
134 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-13 | OABIW | Buy (P) | +200,000 | $1.01M | EDGAR |
| 2023-12-11 | OABIW | Mixed | +17,372 | -$44.5K | EDGAR |
| 2023-11-13 | OABIW | Buy (P) | +95,000 | $405.5K | EDGAR |
| 2023-08-15 | OABIW | Buy (P) | +45,000 | $246.6K | EDGAR |
| 2023-06-12 | OABIW | Buy (P) | +115,000 | $519.8K | EDGAR |
| 2023-05-15 | OABIW | Buy (P) | +440,000 | $1.50M | EDGAR |
| 2023-04-11 | OABIW | Grant (A) | +109,375 | $0 | EDGAR |
| 2023-02-17 | OABIW | Tax (F) | −17,086 | -$64.9K | EDGAR |
| 2023-01-05 | OABIW | Grant (A) | +79,665 | $0 | EDGAR |
| 2023-01-04 | VKTX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.